Drugs that contain Testosterone Undecanoate
1. List of Aveed drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7718640 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
Mar, 2027
(3 years from now) | |
| US8338395 | ENDO PHARMS INC | Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
May, 2027
(4 years from now) | |
Market Authorisation Date: 05 March, 2014
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).
Dosage: INJECTABLE;INTRAMUSCULAR
AVEED family patents
3
United States
2
Russia
2
China
2
Korea, Republic of
2
South Africa
2
ME
2
Denmark
2
European Union
1
Portugal
1
Germany
1
Uruguay
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
IB
1
New Zealand
1
Norway
1
Mexico
1
Argentina
1
Austria
1
Peru
1
Taiwan, Province of China
1
Hong Kong
1
EA
1
Japan
1
Canada
1
Slovenia
1
Saudi Arabia
1
Ukraine
1
Iceland
1
Israel
1
Yugoslavia
1
Poland
1
Chile
1
Australia
1
Ecuador
2. List of Jatenzo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11179402 | CLARUS | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Apr, 2026
(3 years from now) | |
| US10617696 | CLARUS | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11331325 | CLARUS | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Jan, 2027
(3 years from now) | |
| US8241664 | CLARUS | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
Mar, 2029
(6 years from now) | |
| US8778916 | CLARUS | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(7 years from now) | |
| US11426416 | CLARUS | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(7 years from now) | |
| US11179403 | CLARUS | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(7 years from now) | |
| US10543219 | CLARUS | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Apr, 2030
(7 years from now) | |
| US8492369 | CLARUS | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 27, 2022 |
Market Authorisation Date: 27 March, 2019
Treatment: Method of treating testosterone deficiency; A method of treating testosterone deficiency in men
Dosage: CAPSULE;ORAL
JATENZO family patents
27
United States
3
Japan
3
Korea, Republic of
3
European Union
2
Australia
2
Russia
1
Portugal
1
Denmark
1
Spain
1
Canada
1
China
1
Brazil
3. List of Jatenzo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11564933 | TOLMAR | Methods of treating testosterone deficiency |
Apr, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 27, 2022 |
Market Authorisation Date: 27 March, 2019
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: CAPSULE;ORAL
4. List of Kyzatrex drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10576090 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(7 years from now) | |
| US10576089 | MARIUS PHARMS LLC | Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 27, 2025 |
Market Authorisation Date: 27 July, 2022
Treatment: Method of treating testosterone deficiency
Dosage: CAPSULE;ORAL
KYZATREX family patents
12
United States
3
European Union
2
Spain
2
Japan
1
Taiwan, Province of China
1
Portugal
1
Hong Kong
1
New Zealand
1
Poland
1
Canada
1
China
5. List of Tlando drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865695 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US8778922 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US11304960 | ANTARES PHARMA INC | Steroidal compositions |
Jan, 2029
(5 years from now) | |
| US10226473 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11433083 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11364249 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US10716794 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US9949985 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11311555 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US9943527 | ANTARES PHARMA INC | High-strength testosterone undecanoate compositions |
Nov, 2030
(7 years from now) | |
| US11559530 | ANTARES PHARMA INC | Oral testosterone undecanoate therapy |
Nov, 2037
(14 years from now) | |
| US11464735 | ANTARES PHARMA INC | Fixed dose oral testosterone undecanoate compositions and use thereof |
Apr, 2041
(18 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 28, 2025 |
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).
Dosage: CAPSULE;ORAL
TLANDO family patents
55
United States
4
European Union
3
Australia
3
Japan
2
Canada
2
Mexico
2
China
2
Brazil
1
Taiwan, Province of China
1
Korea, Republic of
1
Israel
1
Uruguay
1
Russia
1
South Africa
1
Argentina
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic